Owkin Enters Collaboration Agreement With Msd To Develop Ai-powered Diagnostics For Cancer

Owkin and MSD (Merck & Co., Inc.) have formed a partnership to develop AI-powered digital pathology diagnostics for cancer. The collaboration aims to improve patient diagnosis and treatment. They will create a pre-screening approach for MSI-H (microsatellite instability-high) in various malignancies, with an initial focus on four types in the EU. The goal is to increase screening rates in malignancies with low prevalence, such as endometrial, gastric, small intestine, and biliary cancers, where MSI-H screening is not standard.

This startup proposes to use AI technology to discover more MSI-H cancer patients who could benefit from immune checkpoint inhibitor (ICI) therapy. Both Owkin and MSD see AI's potential in disease detection and patient screening, with the goal of optimizing health care.

A CE-marked MSI digital pathology diagnostic for colorectal cancer is available from Owkin, a biotech company. This cooperation hopes to broaden the application of this technology to new cancer types. Owkin's technique combines human and artificial intelligence to provide patients with individualized care. Their primary goals are to de-risk and accelerate clinical trials, uncover new medicines, and develop AI diagnostics. They use artificial intelligence and federated learning to gain access to current patient data, enhancing precision medicine while protecting patient data privacy.

Read More - bit.ly/3TtdWVx